Bedrijfsoverzicht
Ekso Bionics Holdings, Inc. is a specialized manufacturer focused on the design, development, distribution, and commercialization of wearable robotic exoskeleton products, specifically including the EksoNR and Ekso Indego Therapy devices. The enterprise operates within the Healthcare sector, specifically under the Medical Instruments & Supplies industry, positioning it as a provider of advanced medical technology for rehabilitation and mobility support across the Americas, Europe, the Middle East, Africa, Asia Pacific, and other international markets. The company's scale is defined by a market capitalization of $32.14M, an annual revenue of $12.80M, and an employee base of 50 individuals. These financial metrics indicate that Ekso Bionics operates as a micro-cap entity with a relatively small revenue stream compared to its industry peers, reflecting a niche presence in the broader medical device landscape where the company aims to commercialize its proprietary exoskeleton technology.
Financiële gezondheid
The company reported a revenue of $12.80M over the trailing twelve months, yet it recorded a net income of $-11,921,000 and an EBITDA of $-11,003,000, revealing a significant divergence between top-line sales and bottom-line profitability. This substantial gap between revenue and net income highlights a highly expansive cost structure where operating expenses, likely driven by research, development, and commercialization efforts, far exceed the gross profits generated by product sales. The company generated a free cash flow of $-4,496,125, which indicates a consistent cash burn rate that constrains financial flexibility and suggests the business requires continuous external capital infusion to sustain operations without immediate profitability. Profitability metrics are severely impacted, with a gross margin of 53.5% which is healthy for hardware, but this is counteracted by an operating margin of -119.7% and a profit margin of -91.4%, signaling that the company is currently unable to cover its operating costs with its revenue. On the balance sheet, the company holds $1.17M in cash against $4.64M in debt, resulting in a debt-to-equity ratio of 51.45, which characterizes a highly leveraged financial position rather than a conservative one. Liquidity is assessed via a current ratio of 1.63, which technically suggests the company can cover its short-term liabilities with its current assets, though the magnitude of debt relative to equity complicates this short-term solvency picture. Return on Equity stands at -107.6% and Return on Assets is -33.6%, metrics that collectively reveal that management effectiveness is currently negative as the firm destroys shareholder and asset value due to persistent losses.
Waarderingsbeoordeling
Valuation multiples for the company present a mixed picture, with a P/E Ratio (TTM) listed as N/A due to lack of earnings, while the Forward P/E is -47.47, implying that the market expects earnings to remain negative or for the company to continue burning cash in the foreseeable future. The Price to Book ratio is 3.56, indicating that the stock trades at a significant premium of more than three times its tangible book value, which is an unusual valuation for a company with negative earnings and suggests high market expectations for future recovery or asset appreciation. Alternative valuation metrics such as the Price to Sales ratio of 2.51 and an EV/EBITDA of -3.24 further illustrate that the stock is priced based on revenue and enterprise value rather than earnings power, suggesting investors are betting on future market penetration rather than current performance. The 52-week price range spans from a low of $2.73 to a high of $13.50, and depending on the current trading price, the stock fluctuates within this volatility band, though the exact current price is not provided in the available facts, the range defines the historical trading envelope. The stock exhibits a Beta of 0.78, which means its price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings despite its high-risk financial profile.
Growth & Income
The company's revenue growth over the last year was -38.3%, while the earnings growth rate is N/A, indicating that the business is currently contracting rather than expanding. Since the earnings are negative, a comparison of growth rates between earnings and revenue is not applicable in a traditional sense, but the decline in revenue suggests a contraction in demand, loss of market share, or strategic shifts in product sales that are impacting the top line. Ekso Bionics Holdings, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all of its cash flow to fund operations and R&D rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue trends, a lack of dividend income, and a reliance on external financing to bridge the gap between cash burn and operational needs.